Neuropace
NPCE
39 hedge funds and large institutions have $177M invested in Neuropace in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 7 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
1.15% more ownership
Funds ownership: 44.9% → 46.05% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 44 → 39 (-5)
32% less capital invested
Capital invested by funds: $259M → $177M (-$82M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$2.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$2.35M |
| 4 |
Amundi
Paris,
France
|
+$1.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$542K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$5.45M |
| 2 |
Millennium Management
New York
|
-$1.02M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$952K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$952K |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$735K |
NPCE Hedge Fund Activity: Q3 2021 in Review
39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q3 2021, worth a combined $177M — down 32% from $259M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NPCE and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was Soleus Capital Management, adding an estimated $6M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $5.45M sold.
- 39 institutional investors held Neuropace (NPCE) as of Q3 2021, down from 44 in Q2 2021.
- Funds reported $177M of Neuropace stock for Q3 2021, down 32% quarter-over-quarter.
- 4 funds opened new Neuropace positions in Q3 2021 and 7 closed out, a net change of -3 holders.
- The largest Neuropace buyer in Q3 2021 was Soleus Capital Management, an estimated $6M added.
- The largest Neuropace seller in Q3 2021 was Pura Vida Investments, an estimated $5.45M sold.
Based on aggregated 13F filings for Q3 2021.